We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
AUGTYRO Bristol-Myers Squibb Australia Pty Ltd
Product name
AUGTYRO
Accepted date
May-2024
Active ingredients
repotrectinib
Proposed indication
For the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Application type
A (new medicine)
Publication date
May-2024